National consensus on the management of patients with hyperandrogenism (2016)

    September 2016 in “ Reproductive Endocrinology ”
    В. В. Камінський, Т. Ф Татарчук, Ю.О. Дубоссарська
    Studysummary This review discusses the causes, manifestations, and diagnostic methods of hyperandrogenism in women, highlighting its impact on reproductive function and common dermatological symptoms, and reports no new results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on reproduct-endo.com →
    Discuss this study in the Community →

    Research cited in this study 16

    1. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1 Endocrine Practice · 2015
    2. Polycystic Ovary Syndrome: A Review for Dermatologists Journal of The American Academy of Dermatology · 2014
    3. The Polycystic Ovary Syndrome: A Position Statement from the European Society of Endocrinology European Journal of Endocrinology · 2014
    4. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology and Metabolism · 2013
    5. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome: The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group Fertility and sterility · 2011
    6. Epidemiology, Diagnosis, and Management of Hirsutism: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome Society Human reproduction update · 2011
    7. The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report Fertility and Sterility · 2008
    8. Use of Ethinylestradiol/Drospirenone Combination in Patients with Polycystic Ovary Syndrome Therapeutics and clinical risk management · 2008
    9. Effects of Two Estroprogestins Containing Ethinylestradiol 30 μg and Drospirenone 3 mg and Ethinylestradiol 30 μg and Chlormadinone 2 mg on Skin and Hormonal Hyperandrogenic Manifestations Gynecological endocrinology · 2008
    10. Pharmacologic Therapy of Polycystic Ovary Syndrome Clinical Obstetrics and Gynecology · 2007
    11. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline The Journal of Clinical Endocrinology and Metabolism · 2006
    12. Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred Because of Clinical Hyperandrogenism The Journal of Clinical Endocrinology and Metabolism · 2006
    13. Androgen Excess in Women: Experience with Over 1000 Consecutive Patients The Journal of Clinical Endocrinology and Metabolism · 2004
    14. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS) Human Reproduction · 2003
    15. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders Endocrine practice · 2001
    16. Hirsutism: Evaluation and Treatment Journal of the American Academy of Dermatology · 1985

    Related research 4

    1. Correlation of Clinical and Biochemical Hyperandrogenism in Thai Women with Polycystic Ovary Syndrome Journal of Obstetrics and Gynaecology Research · 2016
    2. Hyperandrogenism in Women: Polycystic Ovary Syndrome Hanyang Medical Reviews · 2012
    3. Diagnosis of Hyperandrogenism: Clinical Criteria Best Practice & Research Clinical Endocrinology & Metabolism · 2006
    4. Spironolactone Therapeutic Effect in the Hyperandrogenism Syndrome Problemy e̊ndokrinologii · 1993